Peptide-based immunotherapy for multiple myeloma: Current approaches

Vaccine

Volumn 28, Issue 37, 2010, Pages 5939-5946

  Zhou, Fu ling ^a   Meng, Shan ^a   Zhang, Wang gang ^a   Wei, Yong chang ^a   Cao, Xing mei ^a   Bai, Gai gai ^a   Wang, Bai yan ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Epitope; Immunotherapy; Multiple Myeloma; Peptide

Indexed keywords

AZACITIDINE; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CANCER TESTIS ANTIGEN; CELL PENETRATING PEPTIDE; CPG OLIGODEOXYNUCLEOTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DICKKOPF 1 PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MELAN A; MUCIN 1; NY ESO 1 ANTIGEN; P21 ACTIVATED KINASE 2; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; WT1 PROTEIN; X BOX BINDING PROTEIN 1; CANCER VACCINE; PEPTIDE;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; PEPTIDES;

EID: 77955513184     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.088     Document Type: Review

References (53)

1. Rosenblatt J., Avigan D. Cellular immunotherapy for multiple myeloma. Best Pract Res Clin Haematol 2008, 21:559-577.
2. Kastritis E., Charidimou A., Varkaris A., Dimopoulos M.A. Targeted therapies in multiple myeloma. Target Oncol 2009, 4:23-36.
3. Perez S.A., von Hofe E., Kallinteris N.L., Gritzapis A.D., Peoples G.E., Papamichail M., et al. A new era in anticancer peptide vaccines. Cancer 2010, 116:2071-2080.
4. Tsuboi A., Oka Y., Nakajima H., Fukuda Y., Elisseeva O.A., Yoshihara S., et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 2007, 86:414-417.
5. Li Z., Oka Y., Tsuboi A., Fujiki F., Harada Y., Nakajima H., et al. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope. Microbiol Immunol 2008, 52:551-558.
6. Oka Y., Tsuboi A., Oji Y., Kawase I., Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008, 20:211-220.
7. Oka Y., Tsuboi A., Fujiki F., Li Z., Nakajima H., Hosen N., et al. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide" -based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. Anticancer Agents Med Chem 2009, 9:787-797.
8. Tang C.K., Katsara M., Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 2008, 7:963-975.
9. Brossart P., Schneider A., Dill P., Schammann T., Grünebach F., Wirths S., et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001, 61:6846-6850.
10. Choi C., Witzens M., Bucur M., Feuerer M., Sommerfeldt N., Trojan A., et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005, 105:2132-2134.
11. Kryukov F., Ocadlíková D., Kovárová L., Buresová I., Hájek R., Michálek J. In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J Immunotoxicol 2009, 6:243-248.
12. Ocadlíková D., Kovárová L., Hájek R., Michálek J. The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase Htert. Klin Onkol 2008, 21:59-65.
13. Schmitt M., Schmitt A., Rojewski M.T., Chen J., Giannopoulos K., Fei F., et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood 2008, 111:1357-1365.
14. Gavriatopoulou M., Dimopoulos M.A., Christoulas D., Migkou M., Iakovaki M., Gkotzamanidou M., et al. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009, 13:839-848.
15. Qian J., Xie J., Hong S., Yang J., Zhang L., Han X., et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 2007, 110:1587-1594.
16. Grube M., Moritz S., Obermann E.C., Rezvani K., Mackensen A., Andreesen R., et al. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res 2007, 13:1053-1060.
17. Hundemer M., Schmidt S., Condomines M., Lupu A., Hose D., Moos M., et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol 2006, 34:486-496.
18. Christensen O., Lupu A., Schmidt S., Condomines M., Belle S., Maier A., et al. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24. J Immunother 2009, 32:613-621.
19. Li G., Hundemer M., Wolfrum S., Ho A.D., Goldschmidt H., Witzens-Harig M. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A). Ann Hematol 2006, 85:583-590.
20. Atanackovic D., Arfsten J., Cao Y., Gnjatic S., Schnieders F., Bartels K., et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007, 109:1103-1112.
21. Andrade V.C., Vettore A.L., Felix R.S., Almeida M.S., Carvalho F., Oliveira J.S., et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008, 8:2.
22. Atanackovic D., Luetkens T., Hildebrandt Y., Arfsten J., Bartels K., Horn C., et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 2009, 15:1343-1352.
23. Tinguely M., Jenni B., Knights A., Lopes B., Korol D., Rousson V., et al. MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci 2008, 99:720-725.
24. Goodyear O., Piper K., Khan N., Starczynski J., Mahendra P., Pratt G., et al. CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood 2005, 106:4217-4224.
25. Goodyear O.C., Pratt G., McLarnon A., Cook M., Piper K., Moss P. Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. Blood 2008, 112:3362-3372.
26. van Rhee F., Szmania S.M., Zhan F., Gupta S.K., Pomtree M., Lin P., et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005, 105:3939-3944.
27. Frank C., Hundemer M., Ho A.D., Goldschmidt H., Witzens-Harig M. Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma 2008, 49:779-785.
28. Bogen B., Ruffini P.A., Corthay A., Fredriksen A.B., Frøyland M., Lundin K., et al. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica 2006, 91:941-948.
29. Cohen S., Haimovich J., Hollander N. B-cell lymphoma and myeloma protection induced by idiotype vaccination with dendritic cells is mediated entirely by T cells in mice. J Immunother 2005, 28:461-466.
30. Hansson L., Rabbani H., Fagerberg J., Osterborg A., Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood 2003, 101:4930-4936.
31. Belle S., Han F., Condomines M., Christensen O., Witzens-Harig M., Kasper B., et al. Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma. Eur J Haematol 2008, 81:26-35.
32. Okochi M., Hayashi H., Ito A., Kato R., Tamura Y., Sato N., et al. Identification of HLA-A24-restricted epitopes with high affinities to Hsp70 using peptide arrays. J Biosci Bioeng 2008, 105:198-203.
33. Gullo C.A., Hwang W.Y., Poh C.K., Au M., Cow G., Teoh G. Use of ultraviolet-light irradiated multiple myeloma cells as immunogens to generate tumor-specific cytolytic T lymphocytes. J Immune Based Ther Vaccines 2008, 6:2.
34. Lotz C., Mutallib S.A., Oehlrich N., Liewer U., Ferreira E.A., Moos M., et al. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL. J Immunol 2005, 175:1301-1309.
35. Sengul S., Li M., Batuman V. Myeloma kidney: toward its prevention-with new insights from in vitro and in vivo models of renal injury. J Nephrol 2009, 22:17-28.
36. Stritzke J., Zunkel T., Steinmann J., Schmitz N., Uharek L., Zeis M. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. Br J Haematol 2003, 120:27-35.
37. Hansson L., Abdalla A.O., Moshfegh A., Choudhury A., Rabbani H., Nilsson B., et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res 2007, 13:1503-1510.
38. Abdalla A.O., Hansson L., Eriksson I., Näsman-Glaser B., Rossmann E.D., Rabbani H., et al. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma-evaluation of T-cell responses by different read-out systems. Haematologica 2007, 92:110-114.
39. Burjanadzé M., Condomines M., Reme T., Quittet P., Latry P., Lugagne C., et al. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol 2007, 139:206-216.
40. Kochenderfer J.N., Chien C.D., Simpson J.L., Gress R.E. Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides. Clin Immunol 2007, 124:119-130.
41. Zhang Y., Wang Z., Zhang J., Farmer B., Lim S.H. Semenogelin I expression in myeloma cells can be upregulated pharmacologically. Leuk Res 2008, 32:1889-1894.
42. Kondo E., Maecker B., Weihrauch M.R., Wickenhauser C., Zeng W., Nadler L.M., et al. Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res 2008, 14:6574-6579.
43. McMahan R.H., Slansky J.E. Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol 2007, 17:317-329.
44. Schiewe A.J., Haworth I.S. Structure-based prediction of MHC-peptide association: algorithm comparison and application to cancer vaccine design. J Mol Graph Model 2007, 26:667-675.
45. Iero M., Filipazzi P., Castelli C., Belli F., Valdagni R., Parmiani G., et al. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?. Cancer Immunol Immunother 2009, 58:1159-1167.
46. May R.J., Dao T., Pinilla-Ibarz J., Korontsvit T., Zakhaleva V., Zhang R.H., et al. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007, 13:4547-4555.
47. Pinilla-Ibarz J., May R.J., Korontsvit T., Gomez M., Kappel B., Zakhaleva V., et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006, 20:2025-2033.
48. Mossman S.P., Evans L.S., Fang H., Staas J., Tice T., Raychaudhuri S., et al. Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants. Vaccine 2005, 23:3545-3554.
49. Szmania S., Gnjatic S., Tricot G., Stone K., Zhan F., Moreno A., et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother 2007, 30:847-854.
50. Ulivieri C., Citro A., Ivaldi F., Mascolo D., Ghittoni R., Fanigliulo D., et al. Antigenic properties of HCMV peptides displayed by filamentous bacteriophages vs. synthetic peptides. Immunol Lett 2008, 119:62-70.
51. Brooks N.A., Pouniotis D.S., Tang C.K., Apostolopoulos V., Pietersz G.A. Cell-penetrating peptides: application in vaccine delivery. Biochim Biophys Acta 2010, 1805:25-34.
52. Pini A., Falciani C., Bracci L. Branched peptides as therapeutics. Curr Protein Pept Sci 2008, 9:468-477.
53. Mocellin S., Pilati P., Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 2009, 16:4779-4796.